Cash Flow Statement continued Reconciliation of Net Cash Flow to Movement in Net Debt Net Cash Notes 2009 2008 2007 $ million $ million $ million  intheyear 44 18 190 Settlement ofcurrencyswaps 12 5 14 Changeinborrowings includingLoanNotes 354 31 1,078 Changeinnetdebt fromnetcashflow 410 18 1,254 Newfinanceleases 7 Facilityfee paid 2 6   31 181 Exchangeadjustment 21 6 72 Changeinnetdebt intheyear 389 22 1,520 Opening net debt net cash 1,332 1,310 210 Closingnetdebt 943 1,332 1,310 Cash and Cash Equivalents For the purposes of the Group Cash Flow Statement cash and cash equivalents at 31 December comprise cashat .
2009 2008 2007 $ million $ million $ million Cash at bankandinhand 192 145 170 Bankoverdrafts 18 23 61 Cash andcashequivalents 174 122 109 30.
Currency Translation The exchange rates used for the translation of currencies into US Dollars that have the most significant  were: Average rates 2009 2008 2007 Sterling 1.56 1.84 2.00 Euro 1.39 1.46 1.37 Swiss Franc 0.92 0.92 0.83 Year-endrates 2009 2008 2007 Sterling 1.61 1.44 1.99 Euro 1.43 1.39 1.46 Swiss Franc 0.97 0.94 0.88 31.
Acquisitions 2009 Plus OrthopedicsHoldings AG In January 2009, the Group reached an agreement with the vendors of Plus to reduce the total original purchase price by CHF159m.
As part of the agreement the Group dropped all its claims and released the vendors from substantially all of the remaining warranties under the original purchase agreement as well as .
Nucryst Pharmaceuticals, Corp. On 22 December 2009, the Group acquired substantially all of the assets and liabilities of Nucryst Pharmaceuticals, Corp, which manufactures and licences exclusively to the Group our range of ACTICOAT products, usingits , SILCRYST.
Acquisitions continued Under the agreement the Group acquired the manufacturing assets from Nucrysts operations in Canada and intellectual property rights relating to the nanocrystalline silver technology used in the manufacture of ACTICOAT product range.
Nucryst has manufactured ACTICOAT products for Smith & Nephew since the .
Pre-acquisition Provisionalfairvalue Fairvalue toGroup carryingamounts adjustments reported in2009 $ million $ million $ million Property, plant andequipment 10 4 6 Intangibleassets acquisition intangibles 12 12 Inventories 4 4  1 1 Deferred taxation 1 1 Net assets 13 9 22  3 Cost ofacquisition 25 Dischargedby: Cash 25 Management believes that goodwill represents the value of the workforce and synergies that are expected toarise fromthecombinedgroup.
As the Group was the only material customer of Nucryst Pharmaceuticals, Corp. no contribution to revenue was achievedin2009.
2008 The aggregate impact of acquisitions that occurred during 2008 is set out below.
The acquisitions primarily relate to minority interest and distributor buyouts, as a result of the Plus acquisition concluded in 2007.
$ million Deferred taxation 1 Intangibleassets 1 Assets acquired 2 Goodwill i 2 Cost ofacquisition Dischargedby Cash 2 Deferred consideration i 2 i  consideration.
Acquisitions continued In2008, deferred considerationof$14minrespect ofthepreviousyears acquisitionswas paid.
2007 Plus OrthopedicsHolding AG On 31 May 2007 the Group acquired 100% of the issued share capital of Plus Orthopedics Holding AG Plus, a private Swiss orthopaedic company for a total of CHF1,086m $889m in cash, including assumed debt.
This has been integrated into the Groups Orthopaedics business segment.
At 31 December 2007 the cost of the Plus acquisition was allocated on a provisional basis to the assets acquired and liabilities assumed on acquisition.
In 2008, fair value adjustments were revised to reflect improved knowledge of the Plus business.
The final allocation of the purchase price that was completed by 31 May 2008 in accordance with the time line stipulated in IFRS 3 Business Combinations and the balance sheet as at 31 December 2007hasbeenadjusted as follows: Pre-acquisition Provisionalfair Fairvalueto Fairvalue to carrying value Groupreported Finalfairvalue Groupreported amounts adjustments in2007 adjustments in2008 $ million $ million $ million $ million $ million Property, plant and equipment 81 2 79 1 78 Intangibleassets acquisition intangibles 240 240 27 213 Intangibleassets other 10 8 2 2 Investment in associates 6 4 10 10 Deferred taxation assets 19 19 Inventories 106 66 172 3 169 Tradeandother receivables 128 128 15 143 Loansandborrowings 181 181 181 Deferred taxation liabilities 4 34 38 7 31 Retirement benefit obligation 6 16 22 22 Tradeandother payables 125 4 129 16 145 Net assets 34 227 261 25 236 Equityattributable tominority interests i 4 4  463 25 488 Cost ofacquisition 720 720 Dischargedby: Cash 726 726 Cash acquiredinPlus 18 18 Costs associated withacquisition 12 12 720 720 i The pre acquisitioncarrying amountoftheequity $4m.
Management believes that goodwill represents the value of the workforce, the existing European corporate  areexpected .
In 2007, from the date of acquisition on 31 May 2007, Plus products contributed $200m to revenue.
It was not practical to calculate Plus  profitin2007, sinceits acquisitionbythe Group, as .
Acquisitions continued As part of the acquisition of Plus, the Group assumed the following minority interests which were previously minorityinterests underthePlusGroup: MinorityInterests Acquired Country % acquired Plus OrthopedicsItaly Srl iv Italy 10% XMedicaSrl iv Italy 10% Plus  BV iv Netherlands 49% Plus OrthopedicsHellas S. A. iv Greece 10% LifeTekLLC i ii US 10% Biograftde Mexico, S. A. fide C. V. i Mexico 12.7% Endoplant GmbH iv Germany 6% Plus OrthopedicsGmbH ii Germany 4%  VertriebsGmbH iii Germany 23.2% i The minority interests in LifeTek LLC and Biograft fide Mexico, S. A. fide C. V. were disposed of in November 2008 generating a lossof $0.6m.
ii These companies wereconsolidated withnorelated minorityinterestdue todeferred purchase consideration agreement.
iii Stillheld at31 December 2009. iv Acquired postacquisition.
Subsequent to the Plus acquisition the Group acquired Plus Australian distributor and the minority interests in the Netherlands and Greece for a total of $13m in cash and $6m of contingent consideration.
This was allocated as inventoryof$3m, goodwillof$ by$4m.
In addition to the above, the Group acquired Plus minority interest in Plus Orthopedics GmbH Germany andtherebysettled deferred $25m.
BlueSky Medical Group, Inc On 10 May 2007, the Group acquired 100% of the issued share capital of BlueSky Medical Group Inc. BlueSky for an initial payment of $15m with further milestone payments related to revenues and other events.
The company has developed products for treating chronic wounds using negative pressure wound therapy and markets a range of negative pressure pumps and wound dressing kits.
This was integrated into the Groups Advanced Wound Management business segment.
BlueSkys assets and liabilities were  at fairvalueat thedate ofacquisitionas follows: Pre-acquisition Fairvalue Fairvalue to carryingamounts adjustments Group $ million $ million $ million Intangibleassets  26 26 Inventories 2 2  1 1  3 3 Deferred taxation liabilities 10 10 Net assets 16 16  34 Cost ofacquisition 50 Dischargedby: Cash 15 Costs associated withacquisition 1 Present valueofprobable milestonepayments 34 50 In addition to the cash consideration of $15m the Group was committed to paying future milestone payments on the achievement of certain events.
As at the date of acquisition, the Group assessed the present valueoftheprobable milestonepayments tobe $34m.
